In vivo applications of magnetic nanoparticle hyperthermia

International Journal of Hyperthermia

Volumn 29, Issue 8, 2013, Pages 828-834

  Hilger, Ingrid ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Active and passive targeting; EPR effect; Iron oxide nanoparticles; Magnetic hyperthermia; Magnetic nanoparticles; Targeted hyperthermia

Indexed keywords

BRADYKININ; CARBOXYMETHYLCELLULOSE; IRON OXIDE; MAGNETIC NANOPARTICLE; MAGNETITE; MESSENGER RNA; NITRIC OXIDE; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; TEMOZOLOMIDE;

ANTIANGIOGENIC THERAPY; BLOOD VESSEL PERMEABILITY; BRAIN BIOPSY; CELL MEMBRANE; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXIC T LYMPHOCYTE; DNA DAMAGE; DNA REPAIR; EXTRACELLULAR SPACE; EXTRAVASATION; GLIOBLASTOMA; GLIOMA; HYPERTHERMIA; HYPERTHERMIC THERAPY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; IRON METABOLISM; LIPID MEMBRANE; LYMPHATIC DRAINAGE; MAGNETIC FIELD; MAGNETIC HYPERTHERMIA; MEMBRANE FLUIDITY; MESENCHYMAL STEM CELL; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROTEIN DENATURATION; REVIEW; SOFT TISSUE SARCOMA; STEREOTACTIC DEVICE; STEREOTACTIC PROCEDURE; SURFACE CHARGE; SWELLING; THERAPY EFFECT; THERMOMETRY; TISSUE PRESSURE; TRANSITION TEMPERATURE; TUMOR CELL; TUMOR NECROSIS; TUMOR RECURRENCE; UTERINE CERVIX CARCINOMA;

ANIMALS; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC PHENOMENA; NANOPARTICLES; NEOPLASMS;

EID: 84887924069     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2013.832815     Document Type: Review

References (63)

1. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002;3(8):487-97. Epub 2002/07/31. (Pubitemid 34863670)
2. Berkov D. Basic Physical Principles. In: Andra W, Nowak H, editors. Magnetism in Medicine, A Handbook. Berlin: Wiley-VCH Verlag GmbH & Co. KGaA; 2007. p. 26-64.
3. Hergt R, Andra W, d'Ambly CG, Hilger I, Kaiser WA, Richter U, et al. Physical limits of hyperthermia using magnetite fine particles. Ieee Transactions on Magnetics 1998;34(5):3745-54.
4. Dewey WC. Arrhenius Relationships from the Molecule and Cell to the Clinic. International Journal of Hyperthermia 1994;10(4): 457-83. (Pubitemid 24224020)
5. Dikomey E, Franzke J. Effect of heat on induction and repair of DNA strand breaks in X-irradiated CHO cells. Int J Radiat Biol 1992;61(2):221-33.
6. Roti Roti JL, Kampinga HH, Malyapa RS, Wright WD, vanderWaal RP, Xu M. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones 1998;3(4):245-55. (Pubitemid 29051824)
7. Li GC, Mivechi NF, Weitzel G. Heat-Shock Proteins, Thermotolerance, and Their Relevance to Clinical Hyperthermia. International Journal of Hyperthermia 1995;11(4):459-88.
8. Suto R, Srivastava PK. A Mechanism for the Specific Immunogenicity of Heat-Shock Protein-Chaperoned Peptides. Science 1995;269(5230):1585-8.
9. Tsan MF, Gao B. Heat shock proteins and immune system. J Leukocyte Biol 2009;85(6):905-10.
10. Hilger I, Rapp A, Greulich KO, Kaiser WA. Assessment of DNA damage in target tumor cells after thermoablation in mice. Radiology 2005;237(2):500-6. (Pubitemid 41509437)
11. Dutz S, Kettering M, Hilger I, Muller R, Zeisberger M. Magnetic multicore nanoparticles for hyperthermia-influence of particle immobilization in tumour tissue on magnetic properties. Nanotechnology 2011;22(26):265102.
12. Horak D, Babic M, Jendelova P, Herynek V, Trchova M, Likavcanova K, et al. Effect of different magnetic nanoparticle coatings on the efficiency of stem cell labeling. J Magn Magn Mater 2009;321(10):1539-47.
13. Neoh KG, Kang ET. Surface modification of magnetic nanoparticles for stem cell labeling. The Royal Society of Chemistry 2012;8:2057-69.
14. Berman SMC, Walczak P, Bulte JWM. Tracking stem cells using magnetic nanoparticles. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology 2011;3(4):343-55.
15. Tantra R, Knight A. Cellular uptake and intracellular fate of engineered nanoparticles: A review on the application of imaging techniques. Nanotoxicology 2011;5(3):381-92.
16. Kettering M, Richter H, Wiekhorst F, Bremer-Streck S, Trahms L, Kaiser WA, et al. Minimal-invasive magnetic heating of tumors does not alter intra-tumoral nanoparticle accumulation, allowing for repeated therapy sessions: an in vivo study in mice. Nanotechnology 2011;22(50):505102.
17. Villanueva A, Canete M, Roca AG, Calero M, Veintemillas-Verdaguer S, Serna CJ, et al. The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells. Nanotechnology 2009;20(11). Doi: 10.1088/0957-4484/20/11/115103.
18. Hilger I, Andra W, Hergt R, Hiergeist R, Schubert H, Kaiser WA. Electromagnetic heating of breast tumors in interventional radiology: In vitro and in vivo studies in human cadavers and mice. Radiology 2001;218(2):570-5. (Pubitemid 32121077)
19. Franke K, Kettering M, Lange K, Kaiser WA, Hilger I. The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein (MRP) expression levels. International journal of nanomedicine 2013;8:351-63.
20. Hori T, Kondo T, Lee H, Song CW, Park HJ. Hyperthermia enhances the effect of beta beta-lapachone to cause gamma gamma H2AX formations and cell death in human osteosarcoma cells. International Journal of Hyperthermia 2011;27(1):53-62.
21. Krupka TM, Dremann D, Exner AA. Time and Dose Dependence of Pluronic Bioactivity in Hyperthermia-Induced Tumor Cell Death. Exp Biol Med 2009;234(1):95-104.
22. Hilger I, Hiergeist R, Hergt R, Winnefeld K, Schubert H, Kaiser WA. Thermal ablation of tumors using magnetic nanoparticles-An in vivo feasibility study. Investigative Radiology 2002;37(10): 580-6.
23. Jordan A, Wust P, Fähling H. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. International Journal of Hyperthermia 1993;9:51-68. (Pubitemid 23052367)
24. Kettering M, Richter H, Wiekhorst F, Bremer-Streck S, Trahms L, Kaiser WA, et al. Minimal-invasive magnetic heating of tumors does not alter intra-tumoral nanoparticle accumulation, allowing for repeated therapy sessions: an in vivo study in mice. Nanotechnology 2011;22(50):505102.
25. Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H, Kobayashi T. Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. Journal of bioscience and bioengineering 2003;96(4):364-9. (Pubitemid 37500209)
26. Ohno T, Wakabayashi T, Takemura A, Yoshida J, Ito A, Shinkai M, et al. Effective solitary hyperthermia treatment of malignant glioma using stick type CMC-magnetite. In vivo study. Journal of Neuro-Oncology 2002;56(3):233-9. (Pubitemid 34476992)
27. Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldofner N, Scholz R, et al. Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. International Journal of Hyperthermia: the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2005;21(7):637-47. (Pubitemid 41684238)
28. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomes. Japanese Journal of Cancer Research 1998;89(7):775-82. (Pubitemid 28401164)
29. Maier-Hauff K, Rothe R, Scholz R, Gneveckow U, Wust P, Thiesen B, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme. Journal of Neuro-Oncology 2007;81(1):53-60. (Pubitemid 44963989)
30. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2010;103(2):317-24.
31. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology 2009;10(5):459-66.
32. van Landeghem FKH, Maier-Hauff K, Jordan A, Hoffmann KT, Gneveckow U, Scholz R, et al. Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. Biomaterials 2009;30(1):52-7.
33. Wust P, Gneveckow U, Johannsen M, Bohmer D, Henkel T, Kahmann F, et al. Magnetic nanoparticles for interstitial thermotherapy-feasibility, tolerance and achieved temperatures. International Journal of Hyperthermia 2006;22(8):673-85. (Pubitemid 46332053)
34. Folkman J. Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease. Nature medicine 1995;1(1):27-31.
35. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release 2000;65(1-2):271-84. (Pubitemid 30122932)
36. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11(17-18):812- 8. (Pubitemid 44280021)
37. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular-Permeability in a Human Tumor Xenograft-Molecular-Size Dependence and Cutoff Size. Cancer Res 1995;55(17):3752-6.
38. Hergt R, Hiergeist R, Hilger I, Kaiser WA, Lapatnikov Y, Margel S, et al. Maghemite nanoparticles with very high AC-losses for application in RF-magnetic hyperthermia. J Magn Magn Mater 2004;270(3):345-57.
39. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Molecular pharmaceutics 2008;5(2):316-27. (Pubitemid 351579134)
40. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: Theory to practice. Pharmacol Rev 2001;53(2):283-318. (Pubitemid 32476118)
41. Hilger I, Kaiser WA. Iron oxide-based nanostructures for MRI and magnetic hyperthermia. Nanomedicine 2012;7(9):1443-59.
42. Ikehara Y, Niwa T, Biao L, Ikehara SK, Ohashi N, Kobayashi T, et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res 2006;66(17):8740-8. (Pubitemid 44449191)
43. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000;60(23):6641-8.
44. Hergt R, Hiergeist R, Zeisberger M, Schuler D, Heyen U, Hilger I, et al. Magnetic properties of bacterial magnetosomes as potential diagnostic and therapeutic tools. J Magn Magn Mater 2005;293(1):80-6. (Pubitemid 40608913)
45. Nacev A, Beni C, Bruno O, Shapiro B. The Behaviors of Ferro-Magnetic Nano-Particles In and Around Blood Vessels under Applied Magnetic Fields. J Magn Magn Mater 2011;323(6): 651-68.
46. Rosensweig RE. Directions in Ferrohydrodynamics. Journal of Applied Physics 1985;57(8):4259-64.
47. Kalambur VS, Han B, Hammer BE, Shield TW, Bischof JC. In vitro characterization of movement, heating and visualization of magnetic nanoparticles for biomedical applications. Nanotechnology 2005;16(8):1221-33. (Pubitemid 40878628)
48. Mejias R, Perez-Yague S, Gutierrez L, Cabrera LI, Spada R, Acedo P, et al. Dimercaptosuccinic acid-coated magnetite nanoparticles for magnetically guided in vivo delivery of interferon gamma for cancer immunotherapy. Biomaterials 2011;32(11): 2938-52.
49. Kong G, Dewhirst MW. Hyperthermia and liposomes. International Journal of Hyperthermia 1999;15(5):345-70. (Pubitemid 29425711)
50. Song CW, Park HJ, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. International Journal of Hyperthermia 2005;21(8):761-7. (Pubitemid 41807103)
51. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 2001;61(7):3027-32. (Pubitemid 32691950)
52. Liu P, Zhang A, Xu Y, Xu LX. Study of non-uniform nanoparticle liposome extravasation in tumour. International Journal of Hyperthermia 2005;21(3):259-70. (Pubitemid 40812742)
53. Yudina A, Moonen C. Ultrasound-induced cell permeabilisation and hyperthermia: Strategies for local delivery of compounds with intracellular mode of action. International Journal of Hyperthermia 2012;28(4):311-9.
54. Satarkar NS, Hilt JZ. Magnetic hydrogel nanocomposites for remote controlled pulsatile drug release. Journal of Controlled Release 2008;130(3):246-51.
55. Yin H, Yu S, Casey PS, Chow GM. Synthesis and properties of poly(D,L-lactide) drug carrier with maghemite nanoparticles. Mat Sci Eng C-Mater 2010;30(4):618-23.
56. Albanese A, Tang PS, Chan WCW. The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems. Annu Rev Biomed Eng 2012;14:1-16.
57. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006;29(1):1-9.
58. Rudnick SI, Adams GP. Affinity and Avidity in Antibody-Based Tumor Targeting. Cancer Biotherapy and Radiopharmaceuticals 2009;24(2):155-61.
59. Le B, Shinkai M, Kitade T, Honda H, Yoshida J, Wakabayashi T, et al. Preparation of tumor-specific magnetoliposomes and their application for hyperthermia. J Chem Eng Jpn 2001;34(1):66-72. (Pubitemid 32682967)
60. DeNardo SJ, DeNardo GL, Miers LA, Natarajan A, Foreman AR, Gruettner C, et al. Development of tumor targeting bioprobes (In-111-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clinical Cancer Research 2005;11(19):7087s-92s. (Pubitemid 41428709)
61. DeNardo SJ, DeNardo GL, Natarajan A, Miers LA, Foreman AR, Gruettner C, et al. Thermal dosimetry predictive of efficacy of In-111-ChL6 nanoparticle AMF-induced thermoablative therapy for human breast cancer in mice. Journal of Nuclear Medicine 2007;48(3):437-44. (Pubitemid 47604930)
62. Hilger I, Leistner Y, Berndt A, Fritsche C, Haas KM, Kosmehl H, et al. Near-infrared fluorescence imaging of HER-2 protein overexpression in tumour cells. Eur Radiol 2004;14:1124-9. (Pubitemid 38787258)
63. Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric Nanoparticles. Molecular pharmaceutics 2010;7(4):1195-208.